Ms1819    (DrugBank: MS-1819)

2 diseases
IDDisease name (Link within this page)Number of trials
298Hereditary pancreatitis2
299Cystic fibrosis5

298. Hereditary pancreatitis    [ 93 clinical trials,   168 drugs,   (DrugBank: 51 drugs),   48 drug target genes,   134 drug target pathways]
Searched query = "Hereditary pancreatitis", "Chronic pancreatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 93 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03481803
(ClinicalTrials.gov)
January 27, 20176/3/2018A Phase IIa Study With Escalating Dose of MS1819-SDA Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal PancreatectomyChronic Pancreatitis;Distal PancreatectomyDrug: MS1819-SDAzurRx SASNULLCompleted18 YearsN/AAll11Phase 2Australia;France;New Zealand
2EUCTR2010-018900-10-FR
(EUCTR)
11/05/201019/03/2010Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitisSafety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitis Exocrine pancreatic insufficiency resulting from chronic pancreatitis
MedDRA version: 12.1;Level: LLT;Classification code 10033628;Term: Pancreatic insufficiency
Product Name: MS1819
Product Code: MS1819
INN or Proposed INN: Yarrowia lipolytica lipase
Laboratoires Mayoly SpindlerNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12France

299. Cystic fibrosis    [ 1,592 clinical trials,   1,539 drugs,   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways]
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 1,592 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04375878
(ClinicalTrials.gov)
July 20, 202030/4/2020OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic FibrosisOPTION 2: A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Exocrine Pancreatic Insufficiency Due to Cystic FibrosisExocrine Pancreatic Insufficiency (EPI);Cystic Fibrosis (CF)Drug: MS1819;Drug: Porcine PERTAzurRx BioPharma, Inc.NULLRecruiting18 YearsN/AAll30Phase 2United States;Poland
2EUCTR2018-003831-31-ES
(EUCTR)
24/01/202002/12/2019MS1819-SD phase II clinical trial for Exocrine Pancreatic Insufficiency caused by Cystic Fibrosis.A multicenter, open-label Phase 2 study with escalating doses of MS1819-SD on top of a stable dose of PPEs, to investigate the efficacy and safety of this combination for the compensation of severe exocrine pancreatic insufficiency in CF patients not fully compensated with only PPEs Exocrine Pancreatic Insufficiency
MedDRA version: 20.0;Level: LLT;Classification code 10033628;Term: Pancreatic insufficiency;System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
AzurRxNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
24Phase 2Hungary;Spain
3NCT04302662
(ClinicalTrials.gov)
June 27, 20194/3/2020Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEsA Multicenter, Open-label Phase 2 Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs, to Investigate the Efficacy and Safety of This Combination for the Compensation of Severe Exocrine Pancreatic Insufficiency in CF Patients Not Fully Compensated With Only PPEsCystic Fibrosis;Cystic Fibrosis Gastrointestinal Disease;Cystic Fibrosis of PancreasDrug: MS1819-SDAzurRx SASNULLRecruiting12 YearsN/AAll24Phase 2Hungary
4EUCTR2018-003831-31-HU
(EUCTR)
28/03/201909/10/2018MS1819-SD phase II clinical trial for Exocrine Pancreatic Insufficiency caused by Cystic Fibrosis.A multicenter, open-label Phase 2 study with escalating doses of MS1819-SD on top of a stable dose of PPEs, to investigate the efficacy and safety of this combination for the compensation of severe exocrine pancreatic insufficiency in CF patients not fully compensated with only PPEs - MS1819/18/02 Exocrine Pancreatic Insufficiency
MedDRA version: 20.0;Level: LLT;Classification code 10033628;Term: Pancreatic insufficiency;System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
AzurRxNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
24Phase 2Hungary
5NCT03746483
(ClinicalTrials.gov)
January 10, 201915/11/2018OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic FibrosisA Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819-SD in Patients With Exocrine Pancreatic Insufficiency Due to Cystic FibrosisExocrine Pancreatic Insufficiency (EPI);Cystic Fibrosis (CF)Drug: MS1819-SD;Drug: Porcine PERTAzurRx BioPharma, Inc.NULLCompleted18 YearsN/AAll32Phase 2United States;Poland